BNP as a marker of the heart failure in the treatment of imatinib mesylate.

Abstract excerpt

Since its introduction 6 years ago, imatinib mesylate, a selective tyrosine kinase inhibitor, has been a phenomenon in treating chronic myelogenous leukemia (CML) with remarkably superior cytogenetic and molecular response rates at all stages of CML followed by longer progression free survival. Despite its extraordinarily high efficacy, adverse effects of imatinib mesylate such as edema, liver toxicity and fluid...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzamides
• Share to Edema
• Share to Exanthema